U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit
17:05 EDT 15 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. District Court for the District of New
Jersey ruled against the company in a patent infringement suit against
Apotex Inc. and Ap...
Other Sources for this Article
Merck
Media Contact: Ron Rogers, (908) 423-6449
Investor
Contact: Carol Ferguson, (908) 423-4465
More From BioPortfolio on "U.S. District Court Rules Against Merck in NASONEX® (mometasone furoate monohydrate) Patent Lawsuit"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
